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Introduction
Inflammation plays a key role in the initiation, develop-
ment and progression of atherosclerosis. The association of   
increased serum levels of acute-phase proteins with the pro-
gression of atherosclerosis and with the occurrence of ath-
erosclerosis-related adverse events, such as coronary heart 
disease and myocardial infarction (MI), has been well docu-
mented in several epidemiological studies.
1-6)
Currently, the pentraxin protein family is divided into two 
subfamilies based on size: the classical “short” pentraxin (25 
kDa) and the “long” pentraxin (40-50 kDa). Pentraxin 3 
(PTX3) is a “long” pentraxin that is highly expressed in the 
heart, whereas C-reactive protein (CRP) is a “short” pentrax-
in and is produced from the liver.
7) In several recent stud-
ies,
8)9) PTX3 appeared to be not only an early indicator of ir-
reversible myocyte injury, but also a prognostic marker in pa-
tients with acute myocardial infarction (AMI).
The global registry of acute coronary events (GRACE) 
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p=0.191), respectively. Among the parameters determining the GRACE risk scores, the degree of Killip class in congestive 
heart failure (CHF) was independently associated with the supramedian PTX3 concentration [odds ratio: 2.229 (95% confi-
dence interval: 1.038-4.787), p=0.040]. Conclusion: The serum PTX3 level provides important information for the risk 
stratification of CHF among the parameters determining the GRACE risk scores in subjects with ACS. (Korean Circ J 
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risk score,
10)11) designed in 94 hospitals and 14 countries, has 
been used as a tool to predict death in-hospital
12) and death 
after discharge
13) in patients with acute coronary syndrome 
(ACS). The GRACE risk score is represented by the following 
three categories; ST segment elevation MI (STEMI), non-ST 
segment elevation MI (NSTEMI), and unstable angina pec-
toris (UAP). ACS represents a broad spectrum of ischemic 
myocardial events including UA, NSTEMI, and STEMI that 
are associated with high morbidity and mortality despite 
early diagnosis, medical intervention and management.
14)  
Our hypothesis is that PTX3 is a prognostic biomarker in 
patients with ACS. We estimated the all-cause mortality or 
death/MI, in-hospital and to 6 months, using the GRACE 
risk scores and compared these estimates to serum PTX3 con-
centrations. The aim of this study was to prove whether the 
value of PTX3 could be a prognostic marker, with the use of 
the GRACE risk assessment tool, in ACS patients.
Subjects and Methods
Subjects
Between July 2007 and June 2008, at the Uijeongbu St. 
Mary’s Hospital, 137 patient subjects with ACS, with or with-
out ST segment elevation, underwent percutaneous coronary 
intervention (PCI); those who had no prior PCI and/or fol-
low-up coronary angiography were enrolled. 
There were 108 male and 29 female patients enrolled, with 
a mean age of 61±12 years. Our institutional review com-
mittee approved this study. Patients were informed of the in-
vestigative nature of the study, and written informed consent 
was obtained before enrollment. 
Definition of acute coronary syndrome 
Patients with ACS were classified into the following stan-
dard subtypes: STEMI, NSTEMI and UAP. The GRACE di-
agnostic criteria of inclusion for AMI, according to the ra-
tionale and design of the GRACE investigators, was met if 
patients had a cardiac ischemic symptom and at least one of 
the following increases in cardiac enzymes: 1) creatine kinase 
MB fraction (CK-MB) >2 times upper limit of the hospital’s nor-
mal range, and/or 2) positive Troponin T result.
10) NSTEMI 
was defined as occurrence of acute MI with positive cardiac 
enzyme results, with or without accompanying electrocar-
diographic changes other than ST segment elevation. STEMI 
was defined as persistent ST segment elevation of ≥1 mm in 2 
contiguous electrocardiographic leads or the presence of a 
new left bundle branch block with positive cardiac enzyme 
results.
10) The diagnostic inclusion criteria for UAP, according 
to the rationale and design of the GRACE investigators, was 
met if patients had a cardiac ischemic symptom with serial en-
zymes and ST segment elevation negative for MI.
10) Patients 
were excluded if they had 1) prior PCI and/or follow-up cor-
onary angiogram, or 2) prior coronary artery bypass graft 
(CABG). 
The global registry of acute coronary events risk as-
sessment tool
Each patient’s individual GRACE risk score, including the 
parameters of age, heart rate, systolic blood pressure, serum 
creatinine level, Killip class, presence of cardiac arrest at ad-
mission, ST segment deviation, and elevated cardiac enzymes 
for all-cause mortality, in-hospital and to 6 months, was cal-
culated using the published risk score calculator from the 
GRACE registry. Full details of the GRACE risk assessment 
tool have been previously published.
10) We estimated the all-
cause mortality or death/MI, in-hospital and to 6 months, us-
ing the GRACE risk scores and compared it with serum PTX3 
concentrations. 
Percutaneous coronary intervention 
A coronary angiogram was performed using the Judkins’ 
method, following the puncture of the femoral artery or via 
a radial artery approach according to current guidelines from 
the American College of Cardiology/American Heart Asso-
ciation/Society for Cardiovascular Angiography and Inter-
vention (ACC/AHA/SCAI) 2005 guideline update for PCI.
15) 
Significant stenosis was defined as a diameter stenosis of 50% 
or greater. A standard antiplatelet therapy and other medica-
tions for ACS were provided according to current guidelines 
from the ACC/AHA
16)17) and the European Society of Cardi-
ology (ESC).
18) In all patients, aspirin (300 mg/day) and clopi-
dogrel (600 mg/day) were loaded before procedure. An intra-
venous bolus of 100 U/kg weight of unfractionated heparin 
was given, and then additional heparin boluses were given to 
maintain an activated clotting time of 250-300 seconds during 
the procedure.
19)20)
Assays
During the procedure, blood was drawn into ethylenedia-
minetetraacetic acid vacuum containers. PTX3 was assayed 
with a noncommercial enzyme linked immuno sorbent assay 
(ELISA), based on the monoclonal antibody MNB10 and rab-
bit anti-serum. The ELISA assay did not cross-react with the 
short pentraxin CRP. 
Statistical analysis
Continuous variables are expressed as mean±standard de-
viation (SD). Group comparisons for continuous variables of 
baseline clinical characteristics were performed using the anal-
ysis of variance test, and analysis for categorical data was per-
formed using the χ2 test. Comparisons between the groups for 
serum PTX3 concentration were analyzed using an indepen-
dent t-test, which was conducted using the SAS statistical soft-
ware, version 9.1 (SAS Institute, Cary, NC, USA). In multivariate 372   Pentraxin 3 and HF With ACS
logistic regression analysis, the value for median serum PTX3 
concentration was used as a cut-off point to determine an 
independent parameter for all-cause mortality in-hospital 
and to 6 months. Statistical significance was set at p<0.05. 
Results
Baseline characteristics
A total of 137 consecutive patients with ACS (mean age, 61± 
12 years, M : F ratio 108 : 29), including 76 (55.5%) with 
STEMI, 38 (27.7%) with NSTEMI, and 23 (16.6%) with UAP, 
were studied. The baseline clinical and laboratory findings 
of the three groups were summarized in Table 1.
Serum pentraxin 3 concentration
The serum PTX3 concentration was not correlated with 
CRP (r=0.199, p=0.058), CK-MB (r=0.022, p=0.830), ischemia 
modified albumin (r=-0.103, p=0.375), brain natriuretic pep-
Table 1. Baseline clinical and laboratory characteristics
Variables STEMI (n=76) NSTEMI (n=38) UAP (n=23) p
Age, years 060±13 063±11 058±12 0.232
Gender, male, n (%) 64 (83.2) 26 (68.4) 18 (78.3) 0.150
Hypertension, n (%) 32 (42.1) 21 (55.3) 13 (56.5) 0.283
Diabetes mellitus, n (%) 21 (27.6) 10 (26.2) 2 (8.7) 0.165
Smoking, n (%) 52 (68.4) 20 (52.6) 14 (60.9) 0.147
Body mass index (kg/m
2)  23.8±4.1 24.1±2.6 24.8±2.8 0.481
Systolic blood pressure (mmHg) 126±25 134±25 134±30 0.211
Diastolic blood pressure (mmHg) 076±14 076±15 075±17 0.957
Heart rate (BPM) 082±25 079±37 065±13 0.038
Respiratory rate (bpm) 23±9 026±17 22±9 0.452
Killip class, n (%) 
I 32 (42.1) 20 (52.6) 20 (87.0) 0.001
II 30 (39.5) 12 (31.6) 1 (4.3) 0.009
III 14 (18.4) 06 (15.8) 2 (8.7) 0.537
Serum creatinine (mg/dL) 01.04±0.30 01.54±2.16 01.16±0.99  0.123
Total cholesterol (mg/dL) 169±41 173±33 186±31 0.228
Triglyceride (mg/dL) 103±75 119±63 168±75 0.003
HDL-C (mg/dL) 38±9 42±9 41±9 0.076
LDL-C (mg/dL) 109±37 105±29 113±26 0.689
C-reactive protein (mg/dL) 02.63±3.94 01.84±2.62 00.37±0.36 0.014
PTX3 (ng/mL) 02.4±2.1 01.9±1.4 01.3±0.9 0.036
CK-MB (ng/mL) 023.8±39.5 016.7±32.3 03.8±1.5 0.056
Troponin T (ng/mL) 00.50±1.07 00.28±0.45 00.02±0.04 0.050
Ischemia modified albumin (U/mL) 097±51 087±22 0120±109 0.203
BNP (pg/mL) 0255±570 00633±1340 037±40 0.137
pro-BNP (pg/mL) 00977±3022 03375±8440 0552±552 0.178
Cardiac arrest, n (%) 4 (5.3) 2 (5.3) 1 (4.3) 0.811
Door to balloon time (hours) 02.6±2.4 08.9±9.7 17.2±7.2 0.001
GRACE risk scores (in-hospital) (%)
All-cause mortality 05.3±5.7 03.1±3.8 01.4±1.8 0.001
Death/MI 18.5±7.0 10.1±5.8 06.4±3.1 <0.0001
GRACE risk scores (to 6 months) (%)
All-cause mortality  09.9±9.1 07.9±8.3 03.6±4.9 0.008
Death/MI 030.0±11.4 021.4±11.1 14.0±7.3 <0.0001
STEMI: ST segment elevation myocardial infarction, NSTEMI: non-ST segment elevation myocardial infarction, UAP: unstable angina 
pectoris, BPM: beats per minute, bpm: breaths per minute, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-
cholesterol, pentraxin 3: PTX3, ck-MB: creatine kinase myoglobulin, BNP: brain natriuretic peptide, pro-BNP: pro-brain natriuretic peptide, 
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tide albumin (r=0.159, p=0.296) and pro-brain natriuretic pep-
tide (r=0.260, p=0.074). The serum PTX3 concentration was 
significantly correlated with Troponin T (r=0.332, p=0.001) 
(Fig. 1).
The serum PTX3 concentration was significantly correlat-
ed to death/MI in-hospital (r=0.242, p=0.015) and death/MI 
to 6 months (r=0.227, p=0.023). The serum PTX3 concentra-
tion was not correlated to all-cause mortality in-hospital (r= 
0.112, p=0.269) and to 6 months (r=0.132, p=0.191) (Table 2).
The serum PTX3 concentration exhibited a significant in-
crease in STEMI (2.4±2.1 ng/mL) as compared to the UAP 
group (1.3±0.9 ng/mL) with a p=0.017. But there was no sig-
nificant difference between the NSTEMI and UAP groups 
(1.9±1.4 ng/mL vs. 1.3±0.9 ng/mL, p=0.083, respectively), 
as well as between the STEMI and NSTEMI groups (2.4±2.1 
ng/mL vs. 1.9±1.4 ng/mL, p=0.185, respectively) (Fig. 2). 
Among the parameters determining the GRACE risk scores, 
the degree of Killip class in congestive heart failure (CHF) was 
independently associated with the supramedian PTX3 con-
centration [odds ratio: 4.221 (95% confidence interval: 1.038-
A  
B  
C  
D  
E  
F  
Fig. 1. The relationship between PTX3 and several biomarkers. PTX3: pentraxin 3, CRP: C-reactive protein, CK-MB: creatine kinase myo-
globulin, IMA: ischemia modified albumin, BNP: brain natriuretic peptide, pro-BNP: pro-brain natriuretic peptide. 
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4.787), p=0.040] (Table 3). 
The cut-off value of serum PTX3 concentration (0.88 ng/
mL) shows a sensitivity (87.5%) and a specificity (69.1%) for 
predicting the probability of all-cause mortality in-hospital 
(>3%), as the highest tertile of GRACE risk assessment, and 
the cut-off value of serum PTX3 concentration (0.92 ng/mL) 
shows a sensitivity (78.2%) and a specificity (50.0%) for predi-
cting the probability of death/MI in-hospital (>5%) (Fig. 3). 
Discussion
Although CRP has been used as a worldwide diagnostic bio-
marker in ischemic heart diseases, the increased serum CRP 
levels in the acute conditions such as ACS have been consid-
ered a nonspecific response to myocardial injury,
21) and the 
Table 2. The relationship between PTX3 and GRACE risk scores
Mean±SD Correlation
with PTX3 p
GRACE risk scores 
  (in-hospital) (%)
All-cause mortality 4.0±5.0 0.112 0.269
Death/MI 14.2±8.0 0.242 0.015
GRACE risk scores 
  (to 6 months) (%)
All-cause mortality 8.3±8.6 0.132 0.191
Death/MI 24.9±12.3 0.227 0.023
PTX3: pentraxin 3, GRACE: global registry of acute coronary events, 
SD: standard deviation, MI: myocardial infarction
Table 3. Multivariate analysis
Variables Odds ratio
95% confidence 
interval
p
Age  1.039 0.996-1.083 0.074
Heart rate  0.995 0.972-1.019 0.706
Systolic blood pressure  0.995 0.976-1.014 0.599
Serum creatinine  0.956 0.485-1.887 0.898
Killip class 2.229 1.038-4.787 0.040
ST segment deviation  1.909 0.778-4.682 0.158
CK-MB  0.998 0.982-1.013 0.096
Troponin T  1.674 0.804-3.485 0.168
Among the parameters determining the GRACE risk scores, the 
degree of Killip class in congestive heart failure was independently 
associated with the supramedian PTX3 concentration (1.47 ng/mL). 
GRACE: global registry of acute coronary events, CK-MB: creatine ki-
nase myoglobulin
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actual role of CRP in the pathogenesis of heart damage is 
still debated.
22)23) Peri et al.
8) reported serum PTX3 as an early 
indicator of AMI in humans and with no correlation be-
tween serum concentrations of PTX3 and CRP. 
The GRACE risk scoring system, a multinational registry 
involving all subsets of ACS including STEMI, NSTEMI and 
UAP, derived from clinical parameters at the time of hospital-
ization, was found to accurately predict mortality at 6 mon-
ths.
10) Parameters in this GRACE scoring system are age, his-
tory of CHF, history of MI, elevated resting heart rate, low sys-
tolic blood pressure on arrival, ST-segment depression, ele-
vated initial serum creatinine, and elevated cardiac enzymes 
in-hospital.
10) Recently, Latini et al.
9) reported the acute-phase 
protein PTX3 as a predictor of 3-month mortality after adjust-
ment for major risk factors and other acute-phase prognostic 
markers. In our results, the role of PTX3 as a prognostic bio-
marker was shown by an increased serum PTX3 that was 
closely related to death due to MI, in-hospital or to 6 months, 
in ACS patients, including STEMI, NSTEMI, and UAP groups. 
Recently, several studies have mentioned that the plasma 
PTX3 level had increased in patients with heart failure and 
was independently associated with an increased risk for car-
diac events.
24)25) Suzuki et al.
24) demonstrated that the concen-
tration of plasma PTX3 levels was significantly higher in pa-
tients with heart failure than in control subjects and increas-
ed with advancing New York Heat Association (NYHA) func-
tional class, especially in severe patients with heart failure 
and NYHA class III or IV. In this study, the serum PTX3 con-
centration was significantly correlated to Troponin T and the 
degree of Killip class, in CHF, among the parameters determin-
ing the GRACE risk scores, and the degree of Killip class was 
independently associated with an incremental change in the 
serum PTX3 level. To establish the role of PTX3 in the patho-
physiology of CHF, further investigations are required in larg-
er populations via multicenter trials. 
Inflammatory mediators are intimately associated with 
the cascade of events leading to atherosclerotic plaque initia-
tion, development, and rupture. A study by Inoue et al.
26) com-
pared 52 patients with stable angina pectoris (SAP) to 16 pa-
tients with UAP and reported that PTX3 was not associated 
with coronary risk factors including hypertension, diabetes 
mellitus and hyperlipidemia; the value of PTX3 was signifi-
cantly higher in the UAP than in the SAP group. They suggest-
ed that the levels of plasma PTX3 had increased in patients 
with arterial inflammation, especially UAP, and that the detec-
tion of PTX3 was due to PTX3 having originated from the 
atherosclerotic plaque itself, thereby reflecting active athero-
sclerosis. Therefore, ‘PTX3’ will be useful for the prediction 
of UAP.
In contrast, Salio et al.
27) reported, in a mouse model, that 
PTX3 plays a nonredundant, regulatory, cardioprotective role 
in AMI and suggested that modulation of the complement 
cascade contributes to the cardioprotective function of PTX3. 
Although our data found much evidence converging to sup-
port Inoue’s report, we need to conduct further research in a 
larger population.
Kotooka et al.
28) reported that PCI also induces a signifi-
cant inflammatory reaction in the injured vessel wall and en-
hances plasma PTX3 concentration that leads to the develop-
ment of neointimal thickening and restenosis after coronary 
stenting. However, to elucidate the mechanism of in-stent re-
stenosis after PCI, more analysis of PTX3 is warranted. 
Limitations
There are several limitations in our present study. First, 
there is the limitation of “time gap” between the sampling of 
PTX3 during the procedure and the calculation of GRACE 
risk score at admission, including the difference of “door to 
balloon time” (STEMI : NSTEMI : UAP; 2.6±2.4 : 8.9±9.7 : 
17.2±7.2, respectively, p=0.001). Second, despite several studi-
es indicating PTX3 as a prognostic biomarker of ACS, a nor-
mal range for PTX3 levels has not been established. Last, our 
investigators suggest that the actual long-term outcomes in 
ACS patient subjects could be confirmed via future follow-
up coronary angiography or telephone interview.
Conclusion
The Killip class that reflects CHF is an independent factor 
associated with an incremental change in the serum PTX3 
level. Our investigators suggest that the serum PTX3 level pro-
vides important information for risk stratification of CHF di-
agnosis, among the parameters determining GRACE risk sco-
res of ACS subjects, including subtypes STEMI, NSTEMI 
and UAP.
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